Pharma — India Patent Cases
742 decisions indexed
Page 18 of 25 · 742 total
Bristol Myers Squibb Holdings Ireland Unlimited Company v.Triveni Interchem Private Limited
The plaintiffs filed a suit seeking an ad interim injunction against the defendants for dealing in generic Apixaban product that infringes Indian Patent No. 247381. The court, relying on previous orders regarding the same patent, passed an ex-parte ad-interim injunction restraining the defendants from manufacturing, selling, or distributing the infringing generic product.
SaNOtize Research and Development Corp. v.Lupin Ltd
SaNOtize Research and Development Corp. filed suit against Lupin Limited alleging infringement of its Nitric Oxide Releasing Solution (NORS) technology, breach of confidentiality, and copyright infringement related to its nasal spray product, NONS/ENOVID. The dispute centers on the use of a proprietary dual-chamber delivery system for nitric oxide in medical treatment. The court granted an interim prohibitory injunction against Lupin's Indian arm and manufacturer.
Pfizer Inc v.Natco Pharma Limited
The court passed several orders regarding various interlocutory applications in the suit filed by Pfizer Inc against Natco Pharma Limited. Specifically, the court granted an undertaking to the defendant that they would provide four weeks prior notice before launching the drug alleged to infringe the patent.
Chugai Seiyaku Kabushiki Kaisha v.Fresenius Kabi Oncology Limited
Chugai Seiyaku Kabushiki Kaisha filed a suit seeking an ad interim injunction against Fresenius Kabi Oncology Limited for infringing Indian Patent No. IN 294424 related to the drug Alectinib. The court granted the injunction, restraining commercial activities, but allowed the defendant to use the product for research purposes under Section 107A of the Patents Act.
PFIZER INC v.NATCO PHARMA LIMITED
The plaintiffs (Pfizer Inc) informed the court that the present matter relates to Patent No. 218291 and is connected to several other pending cases involving the same patent. The court directed that the present matter be listed along with these related matters before the Judge In-charge on September 30, 2021.
Eli Lilly And Company v.Hetero Labs Limited
The plaintiffs allege that the defendants have infringed their patent for Baricitinib by manufacturing and selling it without a license. The case involves a request for an injunction to prevent the defendants from continuing this activity.
Emami Ltd. v.Torque Pharmaceuticals Pvt. Ltd.
Emami Ltd. vs Torque Pharmaceuticals Pvt. Ltd. saw its multi-faceted IP litigation reach a conclusion through settlement in the Calcutta High Court. The original suit, which involved claims of infringement across trademark, copyright, design, and passing off, was formally withdrawn by both parties. The court accepted the Terms of Settlement, decreeing the parent suit and disposing of all connected applications. This resolution allows both companies to move forward without further legal entanglement.
Pfizer Inc v.Triveni Interchem Private Limited
The plaintiff alleges infringement of its Indian Patent No. 218291 related to Palbociclib, marketed under the brand name 'Palbace'. The court found a prima facie case of infringement but noted the timeline of alleged infringement was unclear.
Chugai Seiyaku Kabushiki Kaisha & Anr v.Natco Pharma Limited
Chugai Seiyaku Kabushiki Kaisha filed a suit seeking an ad interim injunction against Natco Pharma Limited, alleging infringement of Indian Patent No. IN 294424 concerning Alectinib. The court allowed the application subject to exceptions and noted that while the defendant could use the drug for research under Section 107A, any commercial launch would require prior permission from the court.
Chugai Seiyaki Kabushiki Kaisha v.MSN Laboratories Private Limited
The plaintiffs filed a suit seeking an ad interim injunction against MSN Laboratories Private Limited for infringing Indian Patent No. IN 294424, which covers Alectinib or its derivatives. The court allowed the application subject to exceptions, permitting the defendant to use the drug for research purposes under Section 107A of the Patents Act, but prohibiting commercial launch without prior court permission.
Sun Pharmaceuticals Industries Ltd v.Union Of India & Ors.
Sun Pharmaceuticals Industries Ltd filed a writ petition seeking directions for the expeditious disposal of opposition proceedings against Patent No. 257402, which was granted to Novo Nordisk A/S. The court addressed the procedural delay and directed the respondents to furnish the Opposition Board's recommendations within one week, subsequently rescheduling the hearing.
Novo Nordisk A/S v.Union Of India & Ors.
Novo Nordisk A/S filed a petition seeking a writ of mandamus to compel Respondent Authorities (No. 1 through No. 3) to decide on its request for the cross-examination of witnesses in a pending post-grant opposition against Patent No. IN 257402. The court, after considering arguments from both sides, directed that Respondent No. 2 fix the date for the cross-examination and complete it expeditiously.
Bristol-Myers Squibb Ireland Unlimited Company v.Micro Labs Limited
The plaintiffs filed a suit seeking permanent injunction against Micro Labs Limited for infringing their registered patent (No. 247381) related to Apixaban, an anticoagulant drug. The court considered the prior history of similar cases and granted an ex-parte ad- interim injunction restraining the defendant from manufacturing or selling generic Apixaban under any brand name, including 'APIVAS'.
Novartis Ag v.Msn Laboratories Pvt Ltd
The plaintiff, Novartis AG, seeks to restrain the defendant from manufacturing Pazopanib Hydrochloride, claiming it infringes their Indian patent. The defendant has obtained approval to manufacture the product, raising concerns of imminent patent infringement.
F.Hoffmann-La Roche Ltd. v.Matrix Laboratories Limited
F.Hoffmann-La Roche Ltd. filed a suit seeking permanent injunction against Matrix Laboratories Limited for infringing Indian Patent No.196774, which relates to a pharmaceutical or chemical compound product. The court ultimately disposed of the suit as no further orders were necessary due to the rejection of leave to institute the suit by the Division Bench.
Novartis Ag & Anr. v.Assistant Controller Of Patents And Designs
Novartis Ag & Anr. filed an appeal challenging the Assistant Controller's refusal to grant their Indian Patent Application No. 10611/DELNP/2015. The court allowed an interlocutory application regarding document filing and issued notice to the Defendant, setting the matter for further hearing.
Indiyaa Distribution Network Llp v.P Singh & Ors.
The Delhi High Court granted an ad-interim injunction in favor of Indiyaa Distribution Network Llp against P Singh & Ors. The Plaintiff, a prior user of the Ayurvedic joint pain relief oil 'SANDHI SUDHA', successfully argued that the Defendants' use of similar marks and imitation of packaging constituted passing off and copyright infringement. The court recognized the Plaintiff's established market presence and sales history to protect consumers from potential confusion.
Sandeep Pandey v.Union Of India And 4 Others
The petitioner filed a PIL seeking directions for the vaccination of citizens between the ages of 18 and 45, and also sought directions under the Patents Act, 1970, to acquire necessary patents for vaccine manufacturing. The court dismissed the petition as the issue was pending before the Apex Court.
Merck Sharp And Dohme Corp. v.Sms Pharmaceuticals Limited
Merck Sharp And Dohme Corp. filed a suit seeking an injunction against Sms Pharmaceuticals Limited for infringing its patent on Sitagliptin, an anti-diabetic drug. The court initially granted an ex-parte ad interim injunction in favor of Merck. However, upon considering the defendant's request under Section 107A (Bolar exemption), the court modified the injunction to allow limited export of the API for research and development purposes.
Astrazeneca Ab v.Intas Pharmaceuticals Limited, Alkem Laboratories Ltd., Zydus Healthcare Limited & Anr., Torrent Pharmaceuticals Limited, Micro Labs Limited, MSN Laboratories Private Limited, Eris Lifesciences Limited, USV Private Limited, Ajanta Pharma Limited
This Delhi High Court judgment addresses multiple appeals filed by AstraZeneca seeking interim relief to restrain various pharmaceutical companies from infringing its patents. The core issue revolved around whether AstraZeneca was entitled to an immediate injunction while the underlying suits for permanent injunction were pending. The court ultimately dismissed all nine appeals, finding no merit in the appellants' claims.
Ms. Mallika Singh Daughter Of Mr. Narendra Singh and Mr. Parth Pareek Son Of Mr. Prem Prakash Pareek v.Union Of India, State Of Rajasthan, Principal Secretary, Department Of Medical, Health And Family Welfare, Government Of Rajasthan
Petitioners filed a Public Interest Litigation seeking directions to the respondents to ascertain if any vaccine is covered by patents, issue compulsory licenses under the Patents Act, share manufacturing trade secrets, and increase vaccine production capacity. The court dismissed the petition, stating that the issues involved relate to policy decisions to be taken by the respondents.
H. Lundbeck A/S v.Symed Labs Limited
The dispute concerned the alleged infringement of Indian Patent No. 227963 by Symed Labs Limited regarding Vortioxetine/Vortioxetine Hydrobromide. The parties amicably resolved the matter, leading to a decree in terms of the settlement agreement.
Merck Sharp And Dohme Corp v.Amoli Organics Private Limited
Merck Sharp And Dohme Corp filed a suit seeking a permanent injunction and damages against Amoli Organics Private Limited for allegedly making, selling, or dealing in products that infringe its Indian Patent No 209816. The dispute centered on the Sitagliptin API and its salts.
Merck Sharp And Dohme Corp v.Solitaire Pharmacia Private Limited
The plaintiffs filed for an ex-parte injunction against the defendants for infringing their Indian Patent No. 209816 related to SITAGLIPTIN and its pharmaceutically acceptable salts. The court found a prima facie case in favor of the plaintiffs.
Merck Sharp And Dohme Corp v.Yms Laboratories Private Limited
The plaintiffs allege that the defendant is infringing their Indian Patent No. 209816 related to SITAGLIPTIN. They seek an injunction to prevent the defendant from manufacturing or selling infringing products.
Natco Pharma Limited v.Union Of India & Ors.
Natco Pharma Limited filed a writ petition challenging the procedural approach of the Patent Controller, arguing that its application for cross-examination of expert witnesses had not been decided. The court observed the long pendency and directed the Controller to first dispose of Natco's cross-examination application before proceeding with the merits of Novartis' patent application.
Dharmendra Kumar Aggarwal v.Govt. Of Nct Of Delhi Through The Secretary & Anr.
This petition addressed the critical issue of supply and availability of the drug Tocilizumab 400 MG (Actemra) for COVID-19 patients in Delhi. The court examined submissions from Roche India, which indicated that global demand far exceeded current manufacturing capabilities. While Roche mentioned partnerships with other entities to meet demand, they provided no clear assurance regarding further supply to India. Consequently, the court issued detailed directions to both Roche and the Union of India to provide comprehensive affidavits on supply chain status, patent details, and potential alternatives.
Centaur Pharmaceuticals Pvt Ltd v.Mhs Pharmaceuticals Pvt Ltd
Centaur Pharmaceuticals filed an Interim Application against MHS Pharmaceuticals. The court noted that the dispute was complex and did not meet the criteria for an immediate ad-interim order, requiring a final hearing after both parties submitted additional evidence.
Pfizer Products Inc v.Unichem Laboratories Limited
The Plaintiffs filed a suit for permanent injunction against the Defendant for infringement of Indian Patents. The parties reached a settlement and withdrew the suit and counter-claim.
Novartis Ag v.Windlas Biotech Pvt Ltd
The case involves a patent infringement dispute where Novartis AG claims that Windlas Biotech Pvt Ltd is infringing on their Indian Patent No. 229051 related to a pharmaceutical composition comprising Sacubitril + Valsartan. The court has previously issued an interim order restraining the defendants from using the infringing product.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.